The effect of text messaging on latent tuberculosis treatment adherence: a randomised controlled trial

James C Johnston, Mia L van der Kop, Kirsten Smillie, Gina Ogilvie, Fawziah Marra, Mohsen Sadatsafavi, Kamila Romanowski, Matthew A Budd, Jan Hajek, Victoria Cook, Richard T Lester, James C Johnston, Mia L van der Kop, Kirsten Smillie, Gina Ogilvie, Fawziah Marra, Mohsen Sadatsafavi, Kamila Romanowski, Matthew A Budd, Jan Hajek, Victoria Cook, Richard T Lester

Abstract

There is limited high-quality evidence available to inform the use of text messaging to improve latent tuberculosis infection (LTBI) treatment adherence.We performed a parallel, randomised controlled trial at two sites to assess the effect of a two-way short message service on LTBI adherence. We enrolled adults initiating LTBI therapy from June 2012 to September 2015 in British Columbia, Canada. Participants were randomised in a 1:1 ratio to standard LTBI treatment (control) or standard LTBI treatment plus two-way weekly text messaging (intervention). The primary outcome was treatment completion, defined as taking ≥80% prescribed doses within 12 months (isoniazid) or 6 months (rifampin) of enrolment. The trial was unblinded except for the data analyst.A total of 358 participants were assigned to the intervention (n=170) and control (n=188) arms. In intention-to-treat analysis, the proportion of participants completing LTBI therapy in the intervention and control arms was 79.4% and 81.9%, respectively (RR 0.97, 95% CI 0.88-1.07; p=0.550). Results were similar for pre-specified secondary end-points, including time-to-completion of LTBI therapy, completion of >90% of prescribed LTBI doses and health-related quality of life.Weekly two-way text messaging did not improve LTBI completion rates compared to standard LTBI care; however, completion rates were high in both treatment arms.

Trial registration: ClinicalTrials.gov NCT01549457.

Conflict of interest statement

Conflict of interest: Disclosures can be found alongside this article at erj.ersjournals.com

Copyright ©ERS 2018.

Source: PubMed

3
S'abonner